Patients’ willingness to travel further to have their cancer surgery at a Centre of Excellence

Abstract

received P+AI (94.2% 1st line; 5.8% ≥2 nd line) and 741 pts received P+F (51.1% 1 st line; 48.9% ≥2 nd line). Mean (SD) age at palbociclib initiation was 62.3 (10.6) years for P+AI and 64.0 (10.0) years for P+F pts. Most pts had a performance status (ECOG) at palbociclib initiation of 0 or 1 (P+AI: 86.4%; P+F: 87.7%). Of those pts with metastatic disease (P+AI: n = 906; P+F: n = 661), 49.2% P+AI and 48.7% P+F pts had visceral disease; 43.5% P+AI and 39.5% P+F pts had bone only metastases.Median follow-up duration from palbociclib initiation was 10.5 months for P+AI and 8.0 months for P+F patients. Overall 80.3% P+AI and 77.5% P+F pts were still on treatment at the time of data collection. Of those initiating at 125 mg/day (P+AI: n = 922, 93.9%; P+F: n = 668, 90.1%), dose reductions occurred in 18.8% P+AI and 11.9% P+F pts. The 12-and 24-month PFR and SR across lines of therapy are presented in Table 1. Pts receiving P+F 1 st line had higher PFR and SR than those receiving 2 nd line or later. PFR and SR outcomes were favorable across subgroups including pt age, ECOG score at palbociclib initiation, visceral status and time from initial to ABC/MBC diagnosis.